Publications | Professor Shudong Wang & Team
Repurposing Existing Therapeutics, Its Importance In Oncology Drug Development: Kinases as a Potential Target
Saiful Islam; Shudong Wang; Nikola Bowden; Jennifer Martin; Richard Head
An Overview of CDK3 in Cancer: Clinical Significance and Pharmacological Implications
Theodosia Teo, Sara Kasirzadeh, Hugo Albrecht, Matthew J. Sykes, Yuchao Yang, Shudong Wang
Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer
US FDA Approved Small-Molecule Kinase Inhibitors for Cancer Therapy
Abraham, D.J., Yu, M., Tadesse, S. and Wang, S. (2022). US FDA-Approved Small-Molecule Kinase Inhibitors for Cancer Therapy. In Burger’s Medicinal Chemistry and Drug Discovery, D.J. Abraham (Ed.). https://doi.org/10.1002/0471266949.bmc214.pub2
An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia
Anshabo AT, Bantie L, Diab S, Lenjisa J, Kebede A, Long Y, Heinemann G, Karanjia J, Noll B, Basnet SKC, Li M, Milne R, Albrecht H, Wang S. Cancers. 2022; 14(5):1113. https://doi.org/10.3390/cancers14051113
A Combination Of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma
Abdullah Al Emran; Hsin-Yi Tseng; Dilini Gunatilake; Stuart J. Cook; Farzana Ahmed; Shudong Wang; Peter Hersey; Stuart J. Gallagher; Jessamy C. Tiffen, Journal of Investigative Dermatology, 2021, https://doi.org/10.3390/cancers14051113
Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation
Mingfeng Yu, Yi Long, Yuchao Yang, Manjun Li, Theodosia Teo, Benjamin Noll, Stephen Philip, Shudong Wang. European Journal of Medicinal Chemistry 218 (2021) 113391, https://doi.org/10.1016/j.ejmech.2021.113391.
Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
Anshabo AT, Milne R, Wang S and Albrecht H (2021) Frontiers in Oncology. 11:678559.
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer
Laychiluh Bantie, Solomon Tadesse, Jimma Likisa, Mingfeng Yu, Benjamin Noll, Gary Heinemann, Noor A. Lokman, Carmela Ricciardelli, Martin K. Oehler, Andrew Beck, Rupal Pradhan, Robert Milne, Hugo Albrecht, Shudong Wang, Gynecologic Oncology, Volume 163, Issue 1, October 2021, Pages 215
Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation
CDK12: a potential therapeutic target in cancer
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S, Drug Discov Today. 2020 Feb;25(2):406-413. doi: 10.1016/j.drudis.2019.12.001.
Targeting CDK9 for treatment of colorectal cancer
Rahaman, M.H., Lam, F., Zhong, L., Teo, T., Adams, J., Yu, M., Milne, R.W., Pepper, C., Lokman, N.A., Ricciardelli, C., Oehler, M.K. and Wang, S. (2019). Mol Oncol, 13: 2178-2193. https://doi.org/10.1002/1878-0261.12559
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia
Rahaman, M.H., Yu, Y., Zhong, L. et al. Invest New Drugs 37, 625–635 (2019).
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Solomon Tadesse, Elizabeth C. Caldon, Wayne Tilley, and Shudong Wang
Journal of Medicinal Chemistry 2019 62 (9), 4233-4251
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents
, , , , , , , , , , , , and (2018) Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. British Journal of Pharmacology, 175: 2399– 2413. doi: 10.1111/bph.13974.
In Search of Novel CDK8 Inhibitors by Virtual Screening
Malika Kumarasiri, Theodosia Teo, Mingfeng Yu, Stephen Philip, Sunita K. C. Basnet, Hugo Albrecht, Matthew J. Sykes, Peng Wang, and Shudong Wang
Journal of Chemical Information and Modeling 2017 57 (3), 413-41
Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells
Shengda Cao, Yingyi Yu, Shangren Chen, Dapeng Lei, Shudong Wang, Xinliang Pan, Jun Peng, Biochemical and Biophysical Research Communications, Volume 482, Issue 4, 2017, Pages 536-541,
Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation
Solomon Tadesse, Mingfeng Yu, Laychiluh B. Mekonnen, Frankie Lam, Saiful Islam, Khamis Tomusange, Muhammed H. Rahaman, Benjamin Noll, Sunita K. C. Basnet, Theodosia Teo, Hugo Albrecht, Robert Milne, and Shudong Wang
Journal of Medicinal Chemistry 2017 60 (5), 1892-1915
A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors
Solomon Tadesse, Ge Zhu, Laychiluh B Mekonnen, Jimma L Lenjisa, Mingfeng Yu, Michael P Brown, and Shudong Wang
Future Medicinal Chemistry 2017 9:13, 1495-1506